Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.82 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7433457 | 0.95 | CHRM1 (0.80) | CHRM1POLBMAPTALDH1A1CYP1A2 | |
| SCHEMBL14565997 | 0.94 | CHRM1 (0.78) | CHRM1POLBMAPTALDH1A1CYP1A2 | |
| Procodazole SCHEMBL838841 | 0.90 | CHRM1 (1.00) | CHRM1POLBMAPTALDH1A1CYP1A2 | |
| Procodazole SCHEMBL29404024 | 0.90 | CHRM1 (1.00) | CHRM1POLBMAPTALDH1A1CYP1A2 | |
| Procodazole SCHEMBL349966 | 0.90 | CHRM1 (1.00) | CHRM1POLBMAPTALDH1A1CYP1A2 | |
| Procodazole SCHEMBL5413283 | 0.86 | CHRM1 (0.91) | CHRM1POLBMAPTALDH1A1CYP1A2 | |
| SCHEMBL18381278 | 0.85 | GAA (0.77) | CHRM1MAPTALDH1A1KDM4EGAA | |
| SCHEMBL1231977 | 0.84 | GAA (0.76) | CHRM1MAPTALDH1A1KDM4EGAA | |
| Bicarbonate SCHEMBL28244886 | 0.83 | POLB (0.68) | CHRM1POLBMAPTALDH1A1CYP1A2 | |
| SCHEMBL7854448 | 0.83 | POLB (0.92) | CHRM1POLBNPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119836236-A | Organic compound | 奇华顿股份有限公司 | 2025-04-15 | — | — | CN | claimed |
| US-20250387374-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | AZURITY PHARMACEUTICALS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3836921-B1 | LIQUID BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | HOSPIRA AUSTRALIA PTY LTD (AU) | 2025-10-08 | — | — | EP | disclosed |
| US-20250302781-A1 | METHOD FOR PRETREATING RELAPSING CANCER | VALCURIA AB (SE) | 2025-10-02 | — | — | US | disclosed |
| US-12419867-B2 | Stable pharmaceutical compositions of bendamustine | AZURITY PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250282895-A1 | PHARMACEUTICAL COMPOSITIONS OF CHEMOTHERAPEUTIC AGENTS BASED ON BETA-SUBSTITUTED BETA-AMINO ACID DERIVATIVES | QUADRIGA BIOSCIENCES, INC. | 2025-09-11 | — | — | US | disclosed |
| US-12246007-B2 | Liquid bendamustine pharmaceutical compositions | HOSPIRA AUSTRALIA PTY LTD (AU) | 2025-03-11 | — | — | US | disclosed |
| US-12208086-B2 | Stable pharmaceutical compositions of bendamustine | SLAYBACK PHARMA LLC (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240350459-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | SLAYBACK PHARMA LLC (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240075014-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | SLAYBACK PHARMA LLC (US) | 2024-03-07 | — | — | US | disclosed |
| WO-2012059935-A1 | PROCESS FOR PREPARING BENDAMUS TINE HYDROCHLORIDE MONOHYDRATE | SHILPA MEDICARE LIMITED (IN) | 2012-05-10 | — | — | WO | disclosed |
| US-20110217258-A1 | Combined Use of Bendamustine, Doxorubicin and Bortezomib for the Treatment of Multiple Myeloma | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-09-08 | — | — | US | disclosed |
| EP-2350665-A1 | COMBINED USE OF BENDAMUSTINE, DOXORUBICIN AND BORTEZOMIB FOR THE TREATMENT OF MULTIPLE MYELOMA | Indiana University Research And Technology Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011079193-A2 | PREPARATION OF BENDAMUSTINE AND ITS SALTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010056733-A1 | COMBINED USE OF BENDAMUSTINE, DOXORUBICIN AND BORTEZOMIB FOR THE TREATMENT OF MULTIPLE MYELOMA | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2026805-A1 | PHARMACEUTICAL COMBINATIONS OF DIAZOLE DERIVATIVES FOR CANCER TREATMENT | Astex Therapeutics Limited (GB) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007129062-A1 | PHARMACEUTICAL COMBINATIONS OF DIAZOLE DERIVATIVES FOR CANCER TREATMENT | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| EP-0869787-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-03-24 | — | — | EP | disclosed |
| EP-0869787-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997024119-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282895-A1 | PHARMACEUTICAL COMPOSITIONS OF CHEMOTHERAPEUTIC AGENTS BASED ON BETA-SUBSTITUTED BETA-AMINO ACID DERIVATIVES | BCAT1, BCAT2, DDC | CHRM1 4605/4885POLB 1661/4885MAPT 685/4885 |
| US-20240350459-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | SORD, NONO, SBDS | CHRM1 3851/4885POLB 1207/4885MAPT 127/4885 |
| US-20240075014-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | SORD, NONO, SBDS | CHRM1 3851/4885POLB 1207/4885MAPT 127/4885 |
| US-12246007-B2 | Liquid bendamustine pharmaceutical compositions | JAK2, SLCO4C1, FGFR3 | CHRM1 3960/4885POLB 1680/4885MAPT 323/4885 |
| US-20110217258-A1 | Combined Use of Bendamustine, Doxorubicin and Bortezomib for the Treatment of Multiple Myeloma | BCL6, BCL3, BCL9 | CHRM1 4848/4885POLB 2492/4885MAPT 1306/4885 |
| US-20250387374-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | BCL6, BCL9, BCL6B | CHRM1 2355/4885POLB 1748/4885MAPT 892/4885 |
| US-12208086-B2 | Stable pharmaceutical compositions of bendamustine | SORD, NONO, SBDS | CHRM1 3851/4885POLB 1207/4885MAPT 127/4885 |
| US-12419867-B2 | Stable pharmaceutical compositions of bendamustine | SORD, NONO, SBDS | CHRM1 3851/4885POLB 1207/4885MAPT 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.